NCT07378839 Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
| NCT ID | NCT07378839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Pregnancy Emesis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-02-10 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-02-10 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.
Eligibility Criteria
Inclusion Criteria: * Pregnant individuals aged 18 years or older * Viable pregnancy with a gestational age between 6 0/7 - 12 6/7 weeks of gestation, confirmed by last menstrual period or ultrasound * Diagnosed with mild to moderate NVP (PUQE-24 score between 4-12) * Ability to understand and read English Exclusion Criteria: * Severe nausea and vomiting, defined as a PUQE score \>12, or diagnosis of hyperemesis gravidarum requiring hospitalization or intravenous fluid therapy * Pre-existing, active or acute respiratory conditions (e.g., asthma, COPD) * History of severe anxiety disorders affecting breathing patterns * Known deviated nasal septum * Nausea and vomiting that pre-dates the pregnancy or is suspected to be due to a etiology other than pregnancy
Contact & Investigator
Shilpa Babbar
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT07378839 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Pregnancy Emesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07378839 currently recruiting?
Yes, NCT07378839 is actively recruiting participants. Contact the research team at obgynresearch@umn.edu for enrollment information.
Where is the NCT07378839 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT07378839 clinical trial?
NCT07378839 is sponsored by University of Minnesota. The principal investigator is Shilpa Babbar at University of Minnesota. The trial plans to enroll 100 participants.